2013
DOI: 10.1182/blood.v122.21.4005.4005
|View full text |Cite
|
Sign up to set email alerts
|

Initial Molecular Response At 3 Months Can Identify Three Groups Of Patients With Different Responses and Event-Free Survival At 36-Months Following Second-Generation Tyrosine Kinase Inhibitor Therapy In Imatinib-Resistant Chronic Myeloid Leukemia

Abstract: Introduction In patients with imatinib-resistant chronic myeloid leukemia (CML) treated with a second generation tyrosine kinase inhibitor (2GTKI), the initial molecular response at 3 months (3m-IMR) has been shown to be predictive of long-term outcomes. However, there is no consensus regarding the best cutoff for the BCR-ABL1 transcript levels, with 1% and 10% being proposed in different studies. Also, additional prognostic factors such as baseline tyrosine kinase (TK) mutations and a progno… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles